Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

Pharma and biotech companies are facing increased competition and rising costs, alongside the ongoing pressure to deliver innovative therapies faster than ever. With R&D expenses climbing and funding often limited, organizations are rethinking how they approach drug development to maximize efficiency and value at every stage, from preclinical research to commercialization.

In this on-demand webinar, industry experts from Thermo Fisher Scientific and Tufts Center for the Study of Drug Development (Tufts), explore key insights from preliminary findings by Tufts, and discuss how integrating CDMO and CRO services and solutions under one comprehensive model can significantly impact the expected Net Present Value (eNPV) of drug development programs.

Watch the on-demand webinar to learn how Thermo Fisher Scientific’s AcceleratorTM Drug Development, "360° CDMO, and CRO services" can improve efficiency, reduce timelines, and help deliver high-quality therapies to patients faster.